



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)
INID code(s) 73

(48) Corrigendum issued on:
13.12.2006 Bulletin 2006/50

(45) Date of publication and mention
of the grant of the patent:
09.08.2006 Bulletin 2006/32

(21) Application number: **99915692.0**

(22) Date of filing: **22.03.1999**

(51) Int Cl.:
A61K 39/295 ^(2006.01) **A61K 39/39** ^(2006.01)
A61K 39/05 ^(2006.01) **A61K 39/08** ^(2006.01)
A61K 39/09 ^(2006.01) **A61K 39/095** ^(2006.01)
A61K 39/10 ^(2006.01) **A61K 39/102** ^(2006.01)
A61K 39/13 ^(2006.01) **A61K 39/29** ^(2006.01)

(86) International application number:
PCT/EP1999/001959

(87) International publication number:
WO 1999/048525 (30.09.1999 Gazette 1999/39)

(54) **HIB/DTPA VACCINE COMPOSITION AND METHODS OF PREPARATION**

HIB/DTPA IMPFSTOFF UND HERSTELLUNGSMETHODEN

COMPOSITION DE VACCIN CONTRE HIB/DTPA ET SES METHODES DE PREPARATION

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
SI

(30) Priority: **25.03.1998 GB 9806456**

(43) Date of publication of application:
10.01.2001 Bulletin 2001/02

(73) Proprietor: **GlaxoSmithKline Biologicals s.a.**
1330 Rixensart (BE)

(72) Inventors:
• **ARTOIS, Claude,**
Glaxosmithkline Biologicals S.A.
B-1330 Rixensart (BE)
• **DE HEYDER, Koen,**
Glaxosmithkline Biologicals S.A.
B-1330 Rixensart (BE)
• **DESMONS, Pierre,**
Glaxosmithkline Biologicals S.A.
B-1330 Rixensart (BE)
• **GARCON, Nathalie,**
Glaxosmithkline Biologicals S.A.
B-1330 Rixensart (BE)
• **MAINIL, Roland,**
Glaxosmithkline Biologicals S.A.
B-1330 Rixensart (BE)

(74) Representative: **Dalton, Marcus Jonathan William**
et al
GlaxoSmithKline
Corporate Intellectual Property (CN9.25.1)
980 Great West Road
Brentford, Middlesex TW8 9GS (GB)

(56) References cited:
WO-A-93/24148 **WO-A-97/00697**
WO-A-97/46255

- **CORBEL M.J. ET AL: "Workshop on Standardisation of Aluminium Adsorbed Vaccines, Bergen, Norway, 21 June 1996." BIOLOGICALS, (1997) 25/3 (351-353). , XP002110484**
- **CORBEL M J: "CONTROL TESTING OF COMBINED VACCINES: A CONSIDERATION OF POTENTIAL PROBLEMS AND APPROACHES" BIOLOGICALS, vol. 22, no. 4, 1 December 1994 (1994-12-01), pages 353-360, XP000603003 ISSN: 1045-1056**
- **ELLIS R W: "Development of combination vaccines" VACCINE, vol. 17, no. 13-14, January 1999 (1999-01), page 1635-1642 XP004158298 ISSN: 0264-410X**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification